Table 1 Baseline characteristics at first treatment combination (N = 1,846)
Characteristics | |
|---|---|
Age, years mean (SD) | 36.9 (10) |
Gender, n (%) | |
- Male | 1,324 (71.7) |
- Female | 520 (28.2) |
- Transgender | 2 (0.1) |
Ethnicity, n (%) | |
- Chinese | 567 (31) |
- Indian | 375 (20) |
- Thai | 502 (27) |
- Others | 402 (22) |
Exposure, n(%) | |
- Heterosexual | 1,333 (72) |
- IDU +others +unknown | 192 (11) |
- Homosexual | 321 (17) |
Income, n (%) | |
- Low income | 451 (24) |
- Lower middle income | 859 (47) |
- Upper middle and high income | 536 (29) |
CD4 cells/μL at baseline, n (%) | |
- < 50 | 432 (23) |
- 51 – 100 | 215 (11) |
- 101 – 200 | 309 (17) |
- > 200 | 232 (13) |
- Missing | 658 (36) |
HIVRNA at baseline, n (%) | |
- < 100,000 | 210 (11) |
- > 100,000 | 256 (14) |
- Missing | 1380 (75) |
Previous AIDS, n(%) | |
- No previous ADI | 1363 (74) |
- Previous ADI | 483 (26) |
First treatment combination, n(%) | |
- d4T/3TC/NVP | 676 (37) |
- 3 or more ART with NNRTI, no PI (other than d4T/3TC/NVP) | 791 (43) |
- 3TC/AZT/EFV | 238 |
- 3TC/d4T/EFV | 165 |
- 3TC/AZT/NVP | 161 |
- ddI/d4T/EFV | 82 |
- ddI/d4T/NVP | 68 |
- ddI/AZT/EFV | 24 |
- ddI/3TC/EFV | 16 |
- others | 37 |
- 3 or more ART, with PI, no NNRTI | 344 (19) |
- Indinavir | 124 |
- Lopinavir | 90 |
- Nelfinavir | 49 |
- Saquinavir | 33 |
- Atazanavir | 20 |
- others | 28 |
- 3 or more ART, NRTI only | 17 (1) |
- ABC/3TC/AZT | 8 |
- ddI/3TC/AZT | 6 |
- others | 3 |
Others | 18 (1) |
Median (IQR) number of drugs | 12 (6 – 16) |